Loading
Futibatinib produced responses in over 40% of patients whose bile duct cancer carried an FGFR2 fusion.
FOENIX-CCA2, trial NCT02052778 sponsored by Taiho and reported in 2022 with publication in the New England Journal of Medicine in 2023, showed that futibatinib produced responses in more than forty percent of patients whose previously treated intrahepatic cholangiocarcinoma carried an FGFR2 rearrangement. It was a single-arm phase 2 of 103 patients with an objective response rate of 42 percent and durable disease control, supporting approval. OnCo links it to biliary tract cancer, FGFR2 as a target, futibatinib and Lipika Goyal. As with pemigatinib, the absence of a randomised comparison leaves open whether an irreversible FGFR inhibitor improves survival over chemotherapy and how it should be sequenced with other FGFR drugs.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
103 enrolled.
Shares Futibatinib, FGFR2, Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
Shares FGFR2, Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
Shares Futibatinib, FGFR2, Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
Shares FGFR2, Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
Shares Futibatinib, Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
Shares Futibatinib, FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.